Namzaric

Product manufactured by Allergan, Inc.

Application Nr Approved Date Route Status External Links
NDA206439 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Namzaric Is Indicated For The Treatment Of Moderate To Severe Dementia Of The Alzheimer's Type In Patients Stabilized On 10 Mg Of Donepezil Hydrochloride Once Daily. Namzaric Is A Combination Of Memantine Hydrochloride, An Nmda Receptor Antagonist, And Donepezil Hydrochloride, An Acetylcholinesterase Inhibitor, Indicated For The Treatment Of Moderate To Severe Dementia Of The Alzheimer's Type In Patients Stabilized On 10 Mg Of Donepezil Hydrochloride Once Daily. ( 1 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 2 Total)

Comments